PLI Payouts Cross ₹21,500 Cr: Pharma, Medtech Among Big Winners

Glimpse:

The Indian government has disbursed ₹21,534 crore under the Production-Linked Incentive (PLI) scheme across 12 sectors, including pharma, medtech, and healthcare. As of March 2025, the scheme has attracted ₹1.76 lakh crore in investments, driven ₹16.5 lakh crore in production and sales, and created over 12 lakh jobs. Pharma and medtech sectors emerged as major beneficiaries, with strong export growth and increased domestic manufacturing.

India’s bold bet on manufacturing is beginning to deliver in a big way. The central government’s Production-Linked Incentive (PLI) schemes, rolled out in 2021 to bolster domestic production and reduce import dependency, have disbursed a cumulative ₹21,534 crore in incentives across 12 critical sectors, including healthcare, pharmaceuticals, and medical devices, as of March 2025.

According to the Ministry of Commerce and Industry, these payouts are fueling a transformative shift in India’s manufacturing capabilities. The flagship initiative has already attracted ₹1.76 lakh crore in investments, generated ₹16.5 lakh crore worth of production and sales, and created over 12 lakh direct and indirect jobs.

“Cumulative incentive amount of ₹21,534 crore has been disbursed under PLI schemes for 12 sectors,” the ministry confirmed in a recent statement.

A Sector-Wide Boost

Spanning sectors such as electronics, IT hardware, bulk drugs, medical devices, pharmaceuticals, telecom, food processing, automobiles, white goods, specialty steel, textiles, and drones, the PLI scheme’s reach is wide and its impact increasingly visible.

At a high-level review meeting held on June 25, Union Commerce & Industry Minister Piyush Goyal urged ministries to chart a five-year roadmap to attract fresh investments and enhance global competitiveness, particularly in skill-intensive sectors.

Pharma and Medtech Lead with High Returns

Among the biggest beneficiaries of the scheme are pharmaceuticals and medical technology (medtech)—sectors that not only delivered impressive production value but also demonstrated India’s growing self-reliance in essential healthcare supplies.

Pharma sector sales under PLI crossed ₹2.66 lakh crore over the last three years

Of this, ₹1.70 lakh crore came from exports, underscoring India’s global reach

Domestic value addition in pharma hit 83.7%, reflecting deepening local supply chains

India reversed its bulk drugs trade deficit—from a ₹1,930 crore shortfall in 2021-22 to a ₹2,280 crore export surplus in 2024-25

Meanwhile, the medical devices industry, one of the newer entrants to the PLI fold, showed strong early momentum. As one of the 12 sectors receiving incentive payouts, medtech is now seen as a high-growth, high-impact vertical in India’s manufacturing roadmap.

“India is not just making for India—it’s making for the world,” noted a senior policy advisor. “The PLI outcomes, particularly in pharma and medtech, are a testament to how strategic incentives can catalyze industrial transformation.”

🎧 Listen to the Summary

Get the key points in just a minute!

💡 Visual Summary

Understand the article in under 60 seconds.